

I-MASK+

PROPHYLAXIS & EARLY OUTPATIENT TREATMENT PROTOCOL FOR COVID-19

IVERMECTIN

Summary of the Clinical Trials Evidence for Ivermectin in COVID-19

Ivermectin, an anti-parasitic medicine whose discovery won the Nobel Prize in 2015, has proven, highly potent, anti-viral and anti-inflammatory properties in laboratory studies. In the past 4 months, numerous, controlled clinical trials from multiple centers and countries worldwide are reporting consistent, large improvements in COVID-19 patient outcomes when treated with ivermectin.

Our comprehensive scientific review of these referenced trials on ivermectin can be found on www.flccc.net/flccc-ivermectin-in-the-prophylaxis-and-treatment-of-covid-19/.

For a quick overview, a **One-page Summary** of our review on ivermectin can be found on www.flccc.net/one-page-summary-of-the-clinical-trials-evidence-for-ivermectin-in-covid-19/

Body weight conversion (kg/lb) for ivermectin dose in prophylaxis and treatment of COVID-19

| Body weight | | Dose | |
|---|------------|---|-------------------------|
| Conversion (1kg = 2.2 lbs) (doses calculated per upper end of weight range) | | 0.2 mg/kg = 0.09 mg/lb (Each tablet = 3 mg; doses rounded to nearest half tablet above) | |
| 70-90 lb | 32-40 kg | 8 mg | (3 tablets = 9 mg) |
| 91-110 lb | 41-50 kg | 10 mg | (3.5 tablets) |
| 111-130 lb | 51-59 kg | 12 mg | (4 tablets) |
| 131-150 lb | 60-68 kg | 13.5 mg | (4.5 tablets) |
| 151-170 lb | 69-77 kg | 15 mg | (5 tablets) |
| 171-190 lb | 78-86 kg | 16 mg | (5.5 tablets) |
| 191-210 lb | 87-95 kg | 18 mg | (6 tablets) |
| 211-230 lb | 96-104 kg | 20 mg | (7 tablets = 21 mg) |
| 231-250 lb | 105-113 kg | 22 mg | (7.5 tablets = 22.5 mg) |
| 251-270 lb | 114-122 kg | 24 mg | (8 tablets) |
| 271-290 lb | 123-131 kg | 26 mg | (9 tablets = 27 mg) |
| 291-310 lb | 132-140 kg | 28 mg | (9.5 tablets = 28.5 mg) |

DISCLAIMER

The *I-Mask+ Prophylaxis & Early Outpatient Treatment Protocol for COVID-19* and the *MATH+ Hospital Treatment Protocol for COVID-19* are solely for educational purposes regarding potentially beneficial therapies for COVID-19. Never disregard professional medical advice because of something you have read on our website and releases. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment in regards to any patient. Treatment for an individual patient should rely on the judgement of your physician or other qualified health provider. Always seek their advice with any questions you may have regarding your health or medical condition.

A summary of the published data supporting the rationale for Ivermectin use in our I-MASK+ protocol can be downloaded from www.flccc.net/i-mask-prophylaxis-treatment-protocol/

For updates, references, and information on the FLCCC Alliance, the I-Mask+ Prophylaxis & Early Outpatient Treatment Protocol for COVID-19 and the MATH+ Hospital Treatment Protocol for COVID-19, please visit our website.